AgeX Therapeutics, Inc

(NYSE MKT:AGE)

Latest On AgeX Therapeutics, Inc (AGE):

Date/Time Type Description Signal Details
2023-05-12 20:16 ESTNewsAgeX Therapeutics GAAP EPS of -$0.09, revenue of $0.01MN/A
2023-04-03 17:09 ESTNewsAgeX Therapeutics GAAP EPS of -$0.28N/A
2023-03-16 14:03 ESTNewsAgeX Therapeutics gets $10M loan ahead of potential restructuringN/A
2022-11-28 07:22 ESTNewsNYSE grants AgeX Therapeutics time extension to regain complianceN/A
2022-11-11 05:50 ESTNewsAgeX Therapeutics GAAP EPS of -$0.06, revenue of $9MN/A
2022-08-13 07:36 ESTNewsAgeX Therapeutics GAAP EPS of -$0.07, revenue of $0.01MN/A
2022-05-14 10:34 ESTNewsAgeX Therapeutics GAAP EPS of -$0.07N/A
2022-03-29 21:35 ESTNewsAgeX Therapeutics GAAP EPS of -$0.23, revenue of $0.14MN/A
2021-12-14 09:40 ESTNewsAgeX forms research collaboration for exosome-based therapies for brain disordersN/A
2021-07-24 07:37 ESTNewsAgeX Therapeutics slumps 10% in trade on terminating LyGenesis merger negotiationsN/A
2021-04-14 21:09 ESTNewsAgeX Therapeutics: New LyGenesis Merger May Unlock Much-Needed ValueN/A
2021-03-11 02:26 ESTNewsAgeX to collaborate with Ohio State University in AgeX-BAT1 researchN/A
2020-12-26 19:22 ESTNewsStocks To Watch: Lemonade, AstraZeneca And FuboTV In The SpotlightN/A
2020-12-13 03:04 ESTFinancialsCompany financials have been released.Neutral
2020-11-25 11:06 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 19:03 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 01:31 ESTNewsAgeX Therapeutics reports Q3 resultsN/A
2020-11-01 16:53 ESTFinancialsCompany financials have been released.Neutral
2020-10-30 09:36 ESTNewsAgeX inks sublicensing pact with ImStem for cell therapy against COVID-19N/A
2020-10-08 15:48 ESTNewsJuvenescence discloses 50% stake in AgeX TherapeuticsN/A
2020-09-26 04:05 ESTFinancialsCompany financials have been released.Neutral
2020-09-15 21:45 ESTInsider TradeMICHAEL D WEST has directly acquired 3,125 shares and currently holds 29,635 shares.Buy
2020-08-16 12:03 ESTFinancialsCompany financials have been released.Neutral
2020-08-15 16:10 ESTNewsAgeX Therapeutics reports Q2 resultsN/A
2020-07-31 00:04 ESTFinancialsCompany financials have been released.Neutral
2020-07-28 15:43 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 16:07 ESTFinancialsCompany financials have been released.Neutral
2020-06-16 23:53 ESTNewsAgeX broadens access to stem cell lines with Pluristyx dealN/A
2020-06-15 21:30 ESTInsider TradeMICHAEL D WEST has directly acquired 3,125 shares and currently holds 27,591 shares.Buy
2020-06-02 18:49 ESTNewsAgeX Therapeutics +12% on ESI 053 deal for COVID-19N/A
2020-05-22 00:44 ESTNewsNew finance chief at AgeX TherapeuticsN/A
2020-05-20 12:11 ESTFinancialsCompany financials have been released.Neutral
2020-05-15 07:48 ESTNewsAgeX Therapeutics reports Q1 resultsN/A
2020-05-03 08:03 ESTFinancialsCompany financials have been released.Neutral
2020-05-01 21:16 ESTNewsAgeX Therapeutics: Revolutionary Potential But Extremely EarlyN/A
2020-04-10 16:33 ESTNewsAgeX licensee on go to start study of cell therapy in MS; shares up 5%N/A
2020-04-10 16:24 ESTNewsAgeX Therapeutics reports FY resultsN/A
2020-04-08 04:03 ESTFinancialsCompany financials have been released.Neutral
2020-04-08 00:03 ESTFinancialsCompany financials have been released.Neutral
2020-04-02 00:02 ESTFinancialsCompany financials have been released.Neutral
2020-03-13 22:00 ESTInsider TradeMICHAEL D WEST has directly acquired 12,500 shares and currently holds 29,551 shares.Buy
2020-03-06 23:02 ESTFinancialsCompany financials have been released.Neutral
2020-02-29 23:03 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 03:02 ESTFinancialsCompany financials have been released.Neutral
2020-01-26 07:02 ESTStock SplitA stock split has occured on May 6, 2015 with a split factor of 15:16.Neutral
2020-01-16 23:03 ESTFinancialsCompany financials have been released.Neutral
2019-12-26 09:43 ESTNewsAgeX announces drawdown of second tranche of loan facilityN/A
2019-12-16 23:02 ESTFinancialsCompany financials have been released.Neutral
2019-11-29 11:31 ESTNewsX, NVAX, PIR and SVRA among midday moversN/A
2019-11-27 23:02 ESTFinancialsCompany financials have been released.Neutral

About AgeX Therapeutics, Inc (AGE):

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; a collaboration with Sernova Corp.; and a research collaboration with The Ohio State University using AgeX's brown adipocyte tissue cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health, and cardiac function. The company was founded in 2017 and is based in Alameda, California.

AGE Quotes by TradingView

See Advanced Chart

General

  • Name AgeX Therapeutics, Inc
  • Symbol AGE
  • Type Common Stock
  • Exchange NYSE MKT
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 17
  • Last Split Factor15:16
  • Last Split Date2015-05-06
  • Fiscal Year EndDecember
  • IPO Date2018-11-29
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.agexinc.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 39.59
  • Price/Book (Most Recent Quarter) 12.96
  • Enterprise Value Revenue 41.93
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Operating Margin -572%
  • Return on Assets -110%
  • Return on Equity -1881%
  • Revenue 1.91 million
  • Earnings Per Share -$0.32
  • Revenue Per Share $0.05
  • Gross Profit 1.48 million
  • Quarterly Earnings Growth 5.6%
View More

Highlights

  • Market Capitalization 70.86 million
  • EBITDA -11527000
  • Book Value Per Share $0.12
View More

Share Statistics

  • Shares Outstanding 37.69 million
  • Shares Float 18.21 million
  • % Held by Insiders 4372%
  • % Held by Institutions 18.29%
  • Shares Short 397157
  • Shares Short Prior Month 363775
  • Short Ratio 0.87
  • Short % of Float 2%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 1.47
  • 52 Week High $3.06
  • 52 Week Low $0.67
  • 50 Day Moving Average 2.16
  • 200 Day Moving Average 1.66
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

AgeX Therapeutics, Inc (AGE) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

AgeX Therapeutics, Inc (AGE) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-16$N/A-$0.07
2020-06-302020-09-30$N/A-$0.07
2020-03-312020-06-30$515000-$0.07
2019-12-312020-03-31$N/A-$0.08
2019-09-302019-12-31$411000-$0.07
2019-06-302019-09-30$380000-$0.09
2019-03-312019-06-30$388000-$0.08
2018-12-312019-03-31$313000-$0.09
2018-09-302018-12-31$380000-$0.09$0.00
2018-06-302018-09-30$15190.95-$0.06$0.00
2018-03-312018-06-30$8200.94-$0.06$0.00
2017-12-312018-03-31$458000-$0.01$0.00
2017-09-302017-12-31$377000-$0.04$0.00
2017-06-302017-09-30$302000-$0.06$0.00
2017-03-312017-06-30$267000-$0.02$0.00
2016-12-312017-03-31$1.67 million-$0.09$0.00

AgeX Therapeutics, Inc (AGE) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A N/A 1.6 million N/A 1.45 million
Income Before Tax N/A N/A -3.22 million N/A -3.22 million
Selling General Administrative N/A N/A 2.07 million N/A 2.19 million
Gross Profit N/A N/A 481000 N/A 362000
Ebit N/A N/A -2.83 million N/A -3.28 million
Operating Income N/A N/A -3.2 million N/A -3.28 million
Income Tax Expense N/A N/A N/A 18000 54000
Total Revenue N/A N/A 515000 N/A 411000
Cost of Revenue N/A N/A 34000 N/A 49000
Total Other Income Expense Net N/A N/A 25000 N/A 56000
Net Income From Continuing Operations N/A N/A -3.22 million N/A -3.28 million
Net Income Applicable to Common Shares -2.54 million -2.69 million N/A -2.71 million -3.22 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A -4000 N/A 77000
Change to Liabilities -32000 -511000 N/A -52000 129000
Total Cash Flow from Investing Activities -12000 -4000 N/A -295000 -157000
Net Borrowings 2 million 2.93 million N/A 1.29 million 487000
Total Cash Flow from Financial Activities N/A N/A 185000 N/A 487000
Change to Operating Activities -46000 118000 N/A -231000 78000
Change in Cash N/A N/A -1.88 million N/A -2.05 million
Total Cash from Operating Activities -1.89 million -2.24 million -2.06 million -2.41 million -2.37 million
Depreciation N/A N/A 367000 N/A 257000
Other Cash Flow from Investing Activities N/A N/A N/A N/A 3000
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A -26000
Other Cash Flow from Financing Activities -23000 -126000 N/A N/A N/A
Change to Net Income 224000 256000 N/A 381000 394000
Capital Expenditures N/A N/A 4000 N/A 237000
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A N/A 5.47 million N/A 3.24 million
Total Stockholder Equity N/A N/A -739000 N/A 4.34 million
Other Current Liabilities 326000 N/A 603000 N/A 219000
Total Assets N/A N/A 5.09 million N/A 8.18 million
Common Stock 4000 4000 N/A 4000 4000
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings -94.63 million -92.08 million -89.4 million -86.21 million -83.5 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets 100000 100000 N/A 111000 193000
Cash N/A N/A 468000 N/A 3.77 million
Total Current Liabilities 4.85 million N/A 5.47 million N/A 2.91 million
Other Stockholder Equity 92000 81000 N/A 69000 74000
Property, Plant & Equipment 442000 681000 N/A 1.13 million 1.01 million
Total Current Assets 1.93 million N/A 2.07 million N/A 4.69 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets -5.38 million -4.32 million N/A 67000 2.05 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A 191000
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1.81 million N/A 1.89 million N/A 333000

AgeX Therapeutics, Inc (AGE) Chart:

AgeX Therapeutics, Inc (AGE) News:

Below you will find a list of latest news for AgeX Therapeutics, Inc (AGE) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

AgeX Therapeutics, Inc (AGE) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest AGE Trades:

Date Shares Price
Jun 13, 2022 7:55 PM EST96$0.77
Jun 13, 2022 7:59 PM EST4$0.77
Jun 13, 2022 7:59 PM EST65$0.77
Jun 13, 2022 7:59 PM EST77$0.77

AgeX Therapeutics, Inc (AGE) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000090866220000130/0000908662-20-000130-index.htm
2020-05-18UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1708599/000000000020004406/0000000000-20-004406-index.htm
2020-06-05UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1708599/000000000020005041/0000000000-20-005041-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708599/000089710119000120/0000897101-19-000120-index.htm
2019-03-26SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708599/000089710119000289/0000897101-19-000289-index.htm
2020-10-16SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708599/000089710120000805/0000897101-20-000805-index.htm
2018-11-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000090866218000231/0000908662-18-000231-index.htm
2018-11-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000090866218000232/0000908662-18-000232-index.htm
2018-11-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000090866218000233/0000908662-18-000233-index.htm
2019-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000090866219000093/0000908662-19-000093-index.htm
2019-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000090866219000094/0000908662-19-000094-index.htm
2019-08-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000090866219000177/0000908662-19-000177-index.htm
2020-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000090866220000071/0000908662-20-000071-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000090866220000130/0000908662-20-000130-index.htm
2020-07-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000090866220000143/0000908662-20-000143-index.htm
2018-12-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708599/000091957418007920/0000919574-18-007920-index.htm
2020-04-06SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1708599/000110465920043662/0001104659-20-043662-index.htm
2020-07-31SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1708599/000110465920089055/0001104659-20-089055-index.htm
2020-10-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000110465920112748/0001104659-20-112748-index.htm
2020-10-07SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1708599/000110465920113076/0001104659-20-113076-index.htm
2018-11-27CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1708599/000114331318000071/0001143313-18-000071-index.htm
2019-02-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708599/000114420419006403/0001144204-19-006403-index.htm
2019-08-16SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1708599/000114420419040399/0001144204-19-040399-index.htm
2018-11-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000115752318002491/0001157523-18-002491-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000115752319000719/0001157523-19-000719-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000115752319001855/0001157523-19-001855-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000115752319002269/0001157523-19-002269-index.htm
2020-03-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000115752320000445/0001157523-20-000445-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000115752320000746/0001157523-20-000746-index.htm
2020-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000115752320000871/0001157523-20-000871-index.htm
2020-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000115752320001186/0001157523-20-001186-index.htm
2018-11-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919118060082/0001209191-18-060082-index.htm
2018-11-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919118060083/0001209191-18-060083-index.htm
2018-11-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919118060084/0001209191-18-060084-index.htm
2018-11-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919118060085/0001209191-18-060085-index.htm
2018-11-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919118060087/0001209191-18-060087-index.htm
2018-11-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919118060088/0001209191-18-060088-index.htm
2018-11-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919118060153/0001209191-18-060153-index.htm
2018-12-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919118062349/0001209191-18-062349-index.htm
2019-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919119010469/0001209191-19-010469-index.htm
2019-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919119010471/0001209191-19-010471-index.htm
2019-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919119010473/0001209191-19-010473-index.htm
2019-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919119010475/0001209191-19-010475-index.htm
2019-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919119019222/0001209191-19-019222-index.htm
2019-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919119019311/0001209191-19-019311-index.htm
2019-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919119019313/0001209191-19-019313-index.htm
2019-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919119019316/0001209191-19-019316-index.htm
2019-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919119019321/0001209191-19-019321-index.htm
2019-03-203/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919119020690/0001209191-19-020690-index.htm
2019-03-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919119020692/0001209191-19-020692-index.htm
2019-08-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919119046922/0001209191-19-046922-index.htm
2019-11-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919119057696/0001209191-19-057696-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919120019073/0001209191-20-019073-index.htm
2020-05-293Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919120033056/0001209191-20-033056-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919120036856/0001209191-20-036856-index.htm
2020-09-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000120919120050615/0001209191-20-050615-index.htm
2017-07-10DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000146257317000001/0001462573-17-000001-index.htm
2018-01-31DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000146257318000001/0001462573-18-000001-index.htm
2018-06-21DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000146257318000002/0001462573-18-000002-index.htm
2018-08-27DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000146257318000003/0001462573-18-000003-index.htm
2019-03-22DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1708599/000146257319000001/0001462573-19-000001-index.htm
2018-06-0810-12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1708599/000149315218008376/0001493152-18-008376-index.htm
2018-07-1910-12B/ARegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1708599/000149315218010218/0001493152-18-010218-index.htm
2018-08-3010-12B/ARegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1708599/000149315218012759/0001493152-18-012759-index.htm
2018-10-2210-12B/ARegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1708599/000149315218014695/0001493152-18-014695-index.htm
2018-11-0510-12B/ARegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1708599/000149315218015167/0001493152-18-015167-index.htm
2018-11-2610-12B/ARegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1708599/000149315218016705/0001493152-18-016705-index.htm
2019-01-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1708599/000149315219001184/0001493152-19-001184-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000149315219002955/0001493152-19-002955-index.htm
2019-03-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000149315219003432/0001493152-19-003432-index.htm
2019-03-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000149315219003740/0001493152-19-003740-index.htm
2019-03-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000149315219004015/0001493152-19-004015-index.htm
2019-04-0110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1708599/000149315219004614/0001493152-19-004614-index.htm
2019-04-3010-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1708599/000149315219006168/0001493152-19-006168-index.htm
2019-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1708599/000149315219007409/0001493152-19-007409-index.htm
2019-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000149315219007417/0001493152-19-007417-index.htm
2019-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000149315219011630/0001493152-19-011630-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1708599/000149315219012634/0001493152-19-012634-index.htm
2019-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000149315219013839/0001493152-19-013839-index.htm
2019-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000149315219014922/0001493152-19-014922-index.htm
2019-10-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000149315219015654/0001493152-19-015654-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1708599/000149315219017440/0001493152-19-017440-index.htm
2019-11-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1708599/000149315219018572/0001493152-19-018572-index.htm
2019-12-03DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1708599/000149315219018658/0001493152-19-018658-index.htm
2019-12-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000149315219019698/0001493152-19-019698-index.htm
2020-01-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000149315220000237/0001493152-20-000237-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000149315220004046/0001493152-20-004046-index.htm
2020-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1708599/000149315220005309/0001493152-20-005309-index.htm
2020-03-3110-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1708599/000149315220005509/0001493152-20-005509-index.htm
2020-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000149315220007466/0001493152-20-007466-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1708599/000149315220008755/0001493152-20-008755-index.htm
2020-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000149315220009644/0001493152-20-009644-index.htm
2020-05-22CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1708599/000149315220009710/0001493152-20-009710-index.htm
2020-05-2210-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1708599/000149315220009712/0001493152-20-009712-index.htm
2020-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000149315220011088/0001493152-20-011088-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000149315220014265/0001493152-20-014265-index.htm
2020-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1708599/000149315220015846/0001493152-20-015846-index.htm
2020-09-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1708599/000149315220018019/0001493152-20-018019-index.htm
2020-11-05PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1708599/000149315220020561/0001493152-20-020561-index.htm
2018-11-27SEC STAFF SEC Staff Action: ORDERhttps://www.sec.gov/Archives/edgar/data/1708599/999999999718009135/9999999997-18-009135-index.htm
2018-11-28CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1708599/999999999718009139/9999999997-18-009139-index.htm

AgeX Therapeutics, Inc (AGE) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of AgeX Therapeutics, Inc (AGE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 4372%
Institutional Ownership: 1829%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-12-10MICHAEL D WESTChief Executive OfficerBuy4,000.003.8615,442.8015,460.00https://www.sec.gov/Archives/edgar/data/1708599/000120919118062349/0001209191-18-062349-index.htm
2019-08-13Ltd Juvenescence10% Share HolderBuy19,000.0016,419,000.00https://www.sec.gov/Archives/edgar/data/1708599/000090866219000177/0000908662-19-000177-index.htm
2020-06-11MICHAEL D WESTChief Executive OfficerBuy3,125.0027,591.00https://www.sec.gov/Archives/edgar/data/1708599/000120919120036856/0001209191-20-036856-index.htm
2020-03-11MICHAEL D WESTChief Executive OfficerBuy12,500.0029,551.00https://www.sec.gov/Archives/edgar/data/1708599/000120919120019073/0001209191-20-019073-index.htm
2020-09-11MICHAEL D WESTChief Executive OfficerBuy3,125.0029,635.00https://www.sec.gov/Archives/edgar/data/1708599/000120919120050615/0001209191-20-050615-index.htm